Patricia Inácio, PhD,  science writer—

Gain Therapeutics has set up a clinical advisory board made up of leading Parkinson’s experts in genetics, biomarkers, and trial design to guide the advancement of GT-02287, its investigational therapy for Parkinson’s disease. The advisory board will collaborate with Gain’s leadership to guide GT-02287 through its potential Phase…

A new screening method may shed light on the interactions between genetic variants that increase the risk of Parkinson’s disease, providing potential avenues for improving risk prediction and personalized care, a study found. The tool, Variant-variant Interaction through Variable Thresholds (VARI3), is designed to detect and interpret how genetic…

The motor cortex, a brain region responsible for movement control, becomes disconnected in levodopa-induced dyskinesia (LID), the uncontrolled movements that occur as a side effect of the drug levodopa in Parkinson’s disease, a study found. Ketamine, an anesthetic used to alleviate LID, was found to restore the motor cortex’s…

Serina Therapeutics has secured $10 million in new funding to support the development of its lead product, SER-252 (POZ-apomorphine), for treating advanced Parkinson’s disease. The goal, according to a company press release, is to advance the candidate therapy toward a Phase 1 clinical trial in patients by…

A fellowship worth more than $1.2 million will fund research focused on improving the mobility of individuals living with Parkinson’s disease. The Advanced Fellowship from the National Institute for Health and Care Research was awarded to Rosie Morris, PhD, director of the Physiotherapy Innovation Laboratory at Northumbria University, in…

Targeting a membrane protein called TMEM16F may help reduce the spread of toxic clumps, or aggregates, of alpha-synuclein — a hallmark of Parkinson’s disease — across the brain, according to a new study by a team in Israel. The scientists found that a genetic variant of the TMEM16F gene…

The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025. BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are…

Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a brain electrode-guided tool for use in neurological brain surgeries, including those for Parkinson’s disease. “As the world’s first FDA [U.S. Food and Drug Administration] cleared system for both diagnostic…

A researcher at the University of Rhode Island has received nearly $500,000 in federal funding to investigate the neuronal changes underlying visual hallucinations — seeing something that is not real — in people with Parkinson’s disease. The funding, from the National Science Foundation, was granted to Yalda Shahriari, PhD,…

Adding Cerevance’s investigational oral therapy solengepras (CVN424) to standard Parkinson’s disease treatment significantly decreased off time, when symptoms return or worsen, according to the data from a completed Phase 2 trial. The trial met its main efficacy goal, with a reduction in average off time at the…